Asymptomatic SARS-CoV-2 infection: is it all about being refractile to innate immune sensing of viral spare-parts?—Clues from exotic animal reservoirs. Issue 1 (8th December 2020)

• Record Type: Journal Article
• Authors: Shankar, Esaki M; Che, Karlhans F; Yong, Yean K; Girija, A S Smiline; Velu, Vijayakumar; Ansari, Abdul W; Larsson, Marie
• Is Part Of: Pathogens and disease. Volume 79:Issue 1(2021)
• Publication Date: 2020-12-08
• Subjects: asymptomatic -- COVID-19 -- evolution -- origin -- monocytes -- SARS-CoV-2; Medical microbiology -- Periodicals; Pathogenic microorganisms -- Periodicals; Communicable diseases -- Microbiology -- Periodicals; Communicable diseases -- Pathogenesis -- Periodicals; Host-parasite relationships -- Periodicals; Systems biology -- Periodicals; 616.904105
• DOI: 10.1093/femspd/ftaa076
• Languages: English
• ISSNs: 2049-632X

Abstract

ABSTRACT: A vast proportion of coronavirus disease 2019 (COVID-19) individuals remain asymptomatic and can shed severe acute respiratory syndrome (SARS-CoV) type 2 virus to transmit the infection, which also explains the exponential increase in the number of COVID-19 cases globally. Furthermore, the rate of recovery from clinical COVID-19 in certain pockets of the globe is surprisingly high. Based on published reports and available literature, here, we speculated a few immunovirological mechanisms as to why a vast majority of individuals remain asymptomatic similar to exotic animal (bats and pangolins) reservoirs that remain refractile to disease development despite carrying a huge load of diverse insidious viral species, and whether such evolutionary advantage would unveil therapeutic strategies against COVID-19 infection in humans. Understanding the unique mechanisms that exotic animal species employ to achieve viral control, as well as inflammatory regulation, appears to hold key clues to the development of therapeutic versatility against COVID-19. Abstract : The authors analyze factors regarding asymptomatic COVID-19 and discuss the importance of identifying key clues to the development of therapeutic versatility against SARS-CoV-2.